{"entity":{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","aka":[],"tldr":"Kevin Harrington is a head and neck oncologist and oncolytic virus pioneer who led the OPTiM trial of T-VEC.","summary":"Kevin Harrington is Professor of Biological Cancer Therapies at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden. His specialisms are head and neck cancer, oncolytic viruses and radiotherapy-immunotherapy combinations. He led OPTiM, the Journal of Clinical Oncology trial showing that talimogene laherparepvec improves durable response rate in advanced melanoma, which brought the oncolytic virus to approval. He now studies combinations of radiotherapy, viruses and immunotherapy in head and neck squamous cell carcinoma and melanoma, including the newer oncolytic agent vusolimogene oderparepvec. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrington%20KJ%5BAuthor%5D%20oncolytic"}],"tags":[],"related":[],"cancers":["head-and-neck","melanoma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["talimogene-laherparepvec","vusolimogene-oderparepvec"],"companies":[],"institutions":["icr-london","royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Biological Cancer Therapies, ICR; Consultant Clinical Oncologist, Royal Marsden","institutionId":"icr-london","specialisms":["Head and neck cancer","Oncolytic viruses","Radiotherapy-immunotherapy combinations"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Harrington%20KJ%5BAuthor%5D%20oncolytic"}],"papers":[{"title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma (OPTiM)","journal":"JCO","year":2015,"doi":"10.1200/JCO.2014.58.3377"},{"title":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","journal":"The Lancet","year":2019,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=KEYNOTE-048+pembrolizumab+head+and+neck+Burtness+Lancet+2019"}]},"route":"/people/kevin-harrington/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"drug":[{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/"},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/"}],"institution":[{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"idea":[{"id":"idea-fund-rt-io-platform","kind":"idea","name":"A neutral platform trial for radiotherapy plus immunotherapy combinations","route":"/ideas/idea-fund-rt-io-platform/"},{"id":"idea-fund-surgeon-scientist-pathway","kind":"idea","name":"Funded research pathways for surgeon-scientists and radiation oncologist-scientists","route":"/ideas/idea-fund-surgeon-scientist-pathway/"},{"id":"idea-bio2-oncolytic-regulated-il12","kind":"idea","name":"Oncolytic viruses that make interleukin-12 only inside the tumour","route":"/ideas/idea-bio2-oncolytic-regulated-il12/"}],"paper":[{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/"}]}}